Sihuan Pharmaceutical Holdings Group (HKG:0460) made a capital increase in Hainan Meifu Medical Device to increase its presence in the aesthetics market, according to a Tuesday filing with the Hong Kong bourse.
Meiyan Space, a non-wholly owned subsidiary of Sihuan, will invest 25.5 million yuan, while Hainan Temmei, a connected party but not a subsidiary of the company, will invest 23.5 million yuan.
This move raised Meifu's registered capital to 50 million yuan, with Meiyan holding 51% and Hainan Temmei 49%.
The pharmaceutical company's shares were 5% higher in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。